We are seeking volunteers for the SURPASS-4 study which is a clinical trial investigating the safety and effectiveness of tirzepatide when taken once weekly compared to insulin taken once daily in people with type 2 diabetes and increased cardiovascular risk.
The primary purpose of the study aims to address the following questions:
- Whether tirzepatide can help study participants with type 2 diabetes
- The safety of tirzepatide and any side effects when taken
- How much tirzepatide should be given to study participants
- How tirzepatide compares to insulin glargine
We are seeking people with a condition, Diabetic Kidney Disease (DKD), to participate in a study. The study is testing a new way of treating DKD with an drug called "propagermanium".
Propagermanium is an experimental treatment in Australia. This means it has not been approved by the Therapeutic Goods Administration for treatment of DKD in Australia however it has been licensed for use in Japan since 1994 for the treatment of chronic hepatitis B infection.
The purpose of this trial is to test if propagermanium is safe and effective in treating participants with DKD who are on a daily dose of 300 mg irbesartan when compared to placebo.
This study will determine how safe and effective the drug is by:
- monitoring symptoms that you may experience while on the study;
- measuring levels of albuminuria and your kidney function during the course of the study;
- measuring the levels of propagermanium and irbesartan that enters your blood and urine.
Primary biliary cholangitis (PBC) is a chronic disease in which the bile ducts in your liver are slowly destroyed. Human studies have shown that seladelpar may be useful for treating the signs and symptoms of PBC and lower alkaline phosphatase (AP) level and decrease itching.
The purpose of this research is to evaluate the safety and effectiveness of an investigational drug, seladelpar, in treating patients with PBC.
The purpose of this study is to find out if Cabozantinib in combination with Atezolizumab is effective in treating liver cancer (hepatocellular carcinoma) compared to Sorafenib alone in people who have not received prior treatment.
This study will also examine how well people with liver cancer who have not received prior treatment tolerate Cabozantinib alone, and how well it works in treating their cancer.
Palmoplantar pustulosis (PPP) is a skin condition that causes blister-like sores to show up on the palms of your hands and the soles of your feet. It can also cause cracked skin or reddened, scaly patches.
CSL324 is a new biological drug, a protein called an antibody. Antibodies are usually produced by special immune cells to fight infections (bacteria, viruses or other intruders into the body). The antibody CSL324 works by blocking the activity of a growth factor called “granulocyte-colony stimulating factor” which is responsible for stimulating the bone marrow to produce white blood cells and stem cells and release them into the bloodstream. Researchers believe this antibody may be able to help decrease inflammation in many inflammatory diseases such as PPP where white blood cells have been mobilised.
CSL324 is an experimental treatment. This means that it has not been approved for treating PPP by the Therapeutic Goods Administration in Australia.
he purpose of the study is to evaluate the safety and effectiveness of the study drug tezepelumab alone, or in combination with a topical corticosteroid, in the treatment of moderate to severe atopic dermatitis. Atopic dermatitis is a chronic, inflammatory skin condition with symptoms including areas of dry, itching and reddened skin. This study will also assess the safety and effectiveness of different doses of tezepelumab.
Tezepelumab is an experimental treatment which means that it is not an approved treatment for moderate to severe atopic dermatitis in Australia. Medications, drugs and devices have to be approved for use by the Therapeutic Goods Administration in Australia.
The purpose of this study is to compare the safety and effectiveness of PRN1008 as a treatment for pemphigus vulgaris (PV) and pemphigus foliaceus (PF) when taken with a corticosteroid and compare this to the safety and effectiveness of corticosteroid alone.
PRN1008 is an investigational drug developed by the study sponsor, Principia for the treatment of autoimmune and inflammatory diseases, such as pemphigus. PRN1008 is a highly selective Bruton’s tyrosine kinase (BTK) inhibitor. BTK is an enzyme that plays a crucial role in B-cell development, a type of white blood cell that is involved in the immune system, and in the white blood cells’ role in diseases like PV or PF.
We are looking for people with Crohn's Disease to participate in a study to determine the safety and effictiveness of a new study medication, guselkumab.
Guselkumab is made in the laboratory and is a fully human monoclonal antibody. An antibody is something that targets and kills foreign objects in the body - in this case, small proteins that are released by cells and affect the behaviour of other cells. This antibody, guselkumab, recognizes and blocks a specific small protein, IL-23, which is important in immune and inflammatory processes.